Literature DB >> 18565507

The human angiotensin AT(1) receptor supports G protein-independent extracellular signal-regulated kinase 1/2 activation and cellular proliferation.

Jakob Lerche Hansen1, Mark Aplin, Jonas Tind Hansen, Gitte Lund Christensen, Marie Mi Bonde, Mikael Schneider, Stig Haunsø, Hans H Schiffer, Ethan S Burstein, David M Weiner, Søren P Sheikh.   

Abstract

The angiotensin AT(1) receptor is a key regulator of blood pressure and body fluid homeostasis, and it plays a key role in the pathophysiology of several cardiovascular diseases such as hypertension, cardiac hypertrophy, congestive heart failure, and arrhythmia. The importance of human angiotensin AT(1) receptor signalling is illustrated by the common use of angiotensin AT(1) receptor-inverse agonists in clinical practice. It is well established that rodent orthologues of the angiotensin AT(1) receptor can selectively signal through G protein-dependent and -independent mechanisms in recombinant expression systems, primary cells and in vivo. The in vivo work clearly demonstrates profoundly different cellular consequences of angiotensin AT(1) receptor signalling in the cardiovascular system, suggesting pharmacological potential for drugs which specifically affect a subset of angiotensin AT(1) receptor actions. However, it is currently unknown whether the human angiotensin AT(1) receptor can signal through G protein-independent mechanisms - and if so, what the physiological impact of such signalling is. We have performed a detailed pharmacological analysis of the human angiotensin AT(1) receptor using a battery of angiotensin analogues and registered drugs targeting this receptor. We show that the human angiotensin AT(1) receptor signals directly through G protein-independent pathways and supports NIH3T3 cellular proliferation. The realization of G protein-independent signalling by the human angiotensin AT(1) receptor has clear pharmacological implications for development of drugs with pathway-specific actions and defined biological outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18565507     DOI: 10.1016/j.ejphar.2008.05.010

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  Probing heterotrimeric G protein activation: applications to biased ligands.

Authors:  Colette Denis; Aude Saulière; Segolene Galandrin; Jean-Michel Sénard; Céline Galés
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Deciphering biased-agonism complexity reveals a new active AT1 receptor entity.

Authors:  Aude Saulière; Morgane Bellot; Hervé Paris; Colette Denis; Frédéric Finana; Jonas T Hansen; Marie-Françoise Altié; Marie-Hélène Seguelas; Atul Pathak; Jakob L Hansen; Jean-Michel Sénard; Céline Galés
Journal:  Nat Chem Biol       Date:  2012-05-27       Impact factor: 15.040

Review 3.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

4.  Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists.

Authors:  Gitte L Christensen; Christian D Kelstrup; Christina Lyngsø; Uzma Sarwar; Rikke Bøgebo; Søren P Sheikh; Steen Gammeltoft; Jesper V Olsen; Jakob L Hansen
Journal:  Mol Cell Proteomics       Date:  2010-04-02       Impact factor: 5.911

5.  An angiotensin II type 1 receptor activation switch patch revealed through evolutionary trace analysis.

Authors:  Marie Mi Bonde; Rong Yao; Jian-Nong Ma; Srinivasan Madabushi; Stig Haunsø; Ethan S Burstein; Jennifer L Whistler; Søren P Sheikh; Olivier Lichtarge; Jakob Lerche Hansen
Journal:  Biochem Pharmacol       Date:  2010-03-21       Impact factor: 5.858

6.  Investigation of the fate of type I angiotensin receptor after biased activation.

Authors:  Gyöngyi Szakadáti; András D Tóth; Ilona Oláh; László Sándor Erdélyi; Tamas Balla; Péter Várnai; László Hunyady; András Balla
Journal:  Mol Pharmacol       Date:  2015-03-24       Impact factor: 4.436

7.  beta-Arrestin 1 and 2 stabilize the angiotensin II type I receptor in distinct high-affinity conformations.

Authors:  S J Sanni; J T Hansen; M M Bonde; T Speerschneider; G L Christensen; S Munk; S Gammeltoft; J L Hansen
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

8.  Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms.

Authors:  Marie Mi Bonde; Jonas Tind Hansen; Samra Joke Sanni; Stig Haunsø; Steen Gammeltoft; Christina Lyngsø; Jakob Lerche Hansen
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

Review 9.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

10.  Functional enhancement of AT1R potency in the presence of the TPαR is revealed by a comprehensive 7TM receptor co-expression screen.

Authors:  Jonas Tind Hansen; Christina Lyngsø; Tobias Speerschneider; Pernille B L Hansen; Céline Galés; David M Weiner; Søren P Sheikh; Ethan S Burstein; Jakob Lerche Hansen
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.